E-Therapeutics Plc (BE:ETXP) has announced an update on its collaboration with C4X Discovery (C4XD) on novel interventions in Parkinson’s disease (PD). The PD collaboration started in May 2018 and combines the network-driven drug discovery (NDD) platform at ETX with the genetic information from C4XD’s platform. This has already resulted in a number of avenues for novel drug target generation in PD.
Good business development ammunition
Significant progress in the PD collaboration may not yet be the announcement of a licensing transaction that investors have been patiently waiting for. It is, however, a further demonstration that ETX’s NDD platform might yield novel drug targets in PD and adds to its existing capabilities in the tryptophan catabolism and immune checkpoint modulator programmes. We expect ETX’s management to be in constant business development mode in selling the benefits of its platform and its two assets available for licensing, so this announcement on advances in a neurological indication can only aid that process.
To read the entire report Please click on the pdf File Below..